Businesses
News releases, reports, statements and associated documents from U.S. and international businesses.
Featured Stories
UL Solutions to Showcase Advances in Automotive Safety and Performance at Taipei AMPA
TAIPEI, Taiwan, April 19 -- UL Solutions, a company that says it delivers testing, inspection and certification services, together with software products and advisory offerings, issued the following news release:
UL Solutions (NYSE: ULS), a global safety science leader, will debut at this year's Taipei International Auto Parts and Accessories Show. The company will present a full range of services spanning automotive power systems, electronic components, parts and materials at the event. UL Solutions will also highlight its capabilities in assisting suppliers in optimizing product development
... Show Full Article
TAIPEI, Taiwan, April 19 -- UL Solutions, a company that says it delivers testing, inspection and certification services, together with software products and advisory offerings, issued the following news release:
UL Solutions (NYSE: ULS), a global safety science leader, will debut at this year's Taipei International Auto Parts and Accessories Show. The company will present a full range of services spanning automotive power systems, electronic components, parts and materials at the event. UL Solutions will also highlight its capabilities in assisting suppliers in optimizing product developmentprocesses to seize innovative opportunities in the evolving automotive industry.
The Taipei International Auto Parts and Accessories Show, also known as the Taipei AMPA and Autotronics Taipei, will take place April 17-20, 2024, at the Taipei Nangang Exhibition Center, Hall 1, Taipei, Taiwan. The event will showcase the automotive aftermarket industry, including auto parts, chassis systems, electrical equipment, frames, engines and auto parts.
With the rapid evolution of the automotive industry, driven by innovations in automation, electrification and connectivity technologies, there is a significant shift in the design of vehicle components and electronic systems. This presents safety and performance challenges and opportunities for automotive stakeholders.
The increasing use of electronic products in vehicles and the proliferation of connected cars have heightened cybersecurity concerns, driving the automotive cybersecurity market, estimated to reach $3.66 billion (USD) in 2023 and projected to reach $16.43 billion (USD) by 2032.1 To penetrate the EV markets swiftly, parts suppliers must prioritize the safety compliance of vehicle components.
"The automotive industry continues to evolve quickly, with consumer expectations and technology serving as catalysts for these changes," said Jonathan TH Chen, regional vice president of UL Solutions in Taiwan. "As the industry embraces product and process transformations and finds innovative ways to support autonomous technology, connectivity, electrification and shared mobility, UL Solutions is prepared to help original equipment manufacturers, their suppliers and auto tech startups innovate safely, speed products to market and improve efficiency."
With over 35 years of experience in Taiwan, UL Solutions operates state-of-the-art testing facilities in Taipei, Taoyuan and Hsinchu. These facilities provide testing and evaluation for domestic automotive parts suppliers, including local service capabilities and advisory services to help understand product safety, security and sustainability.
UL Solutions will showcase its services for automotive products at booth #K0126 and offer safety advisory and on-site testing demonstrations at its product safety check-up zone. In the forum "Innovation and Reinvention of Automotive Safety and New Energy" during the exhibition, Cyril Mancel, global sales director of engineered materials of UL Solutions, will share his insights on global automotive trends and requirements.
* * *
About UL Solutions
A global leader in applied safety science, UL Solutions (NYSE: ULS) transforms safety, security and sustainability challenges into opportunities for customers in more than 100 countries. UL Solutions delivers testing, inspection and certification services, together with software products and advisory offerings, that support our customers' product innovation and business growth. The UL Mark serves as a recognized symbol of trust in our customers' products and reflects an unwavering commitment to advancing our safety mission. We help our customers innovate, launch new products and services, navigate global markets and complex supply chains, and grow sustainably and responsibly into the future. Our science is your advantage.
* * *
Source:
1(Automotive Cybersecurity Market Size To Hit USD 16.43 Bn By 2032) (https://www.precedenceresearch.com/automotive-cybersecurity-market), Precedence Research, 2023/3
* * *
Original text here: https://www.ul.com/news/ul-solutions-showcase-advances-automotive-safety-and-performance-taipei-ampa
[Category: BizLaboratory Sciences]
Memorial and Solis Mammography Open New Community-Based Breast Imaging Centers in Weston, Plantation, and Palm Springs North
HOLLYWOOD, Florida, April 19 -- Memorial Health System issued the following news release:
Memorial Healthcare System and Solis Mammography, are pleased to announce the opening of the collaboration's first community-based breast screening centers in Weston, Plantation and Palm Springs North near Hialeah and Miami Lakes. The centers represent the commitment that both organizations have made to expand access to state-of-the art breast imaging services through convenient, easily accessible locations across South Florida.
The innovative collaboration between the nation's largest independent breast
... Show Full Article
HOLLYWOOD, Florida, April 19 -- Memorial Health System issued the following news release:
Memorial Healthcare System and Solis Mammography, are pleased to announce the opening of the collaboration's first community-based breast screening centers in Weston, Plantation and Palm Springs North near Hialeah and Miami Lakes. The centers represent the commitment that both organizations have made to expand access to state-of-the art breast imaging services through convenient, easily accessible locations across South Florida.
The innovative collaboration between the nation's largest independent breastwellness leader and the renowned South Florida-based public healthcare system launched in the first quarter of 2023 with Solis Mammography assuming the management of Memorial's hospital-based women's imaging centers at Memorial Regional Hospital, Memorial Regional Hospital South, Memorial Hospital West and Memorial Hospital Miramar.
"Empowering South Florida's vibrant women, Memorial and Solis Mammography have united to provide seamless access to breast screenings," said Leah A. Carpenter, Chief Operating Officer of Memorial Healthcare System. "Together, we prioritize women's health, ensuring a pathway from preventative care to the compassionate support of Memorial Cancer Institute, because every woman's well-being and health journey deserves unwavering commitment."
"Convenient, community-based access to advanced mammography screening services is the key to saving more lives," said Grant Davies, president and CEO of Solis Mammography. "As we build on our strong alliance with Memorial to reach more women across South Florida, we'll be able to expand upon our shared mission of detecting more breast cancers at even earlier stages."
Each of the breast screening centers offers leading-edge technology, along with a team of experienced and compassionate healthcare professionals who are committed to providing the highest standard of breast imaging to residents in the community.
Key features of the community-based locations:
* 3D Mammography and SmartCurve: Solis Mammography's innovation-driven screening platform includes 3D mammography for greater accuracy, and SmartCurve technology for a more comfortable mammogram. Dense breast ultrasound is also offered as a supplemental screening tool.
* Patient-Centered Care: Each of the three community-based centers are designed with patient comfort and convenience in mind, ensuring a welcoming and stress-free environment for every patient.
* Convenient Scheduling: With flexible appointments, online scheduling and extended hours, women in the Weston, Plantation and Palm Springs North areas can now more easily prioritize their breast health. Screening mammograms may be scheduled online without a doctor's order. An order is required for scheduling dense breast ultrasound. To schedule a mammogram, go online to Solis Mammography, or call 855-530-2383.
* * *
About Solis Mammography
Solis Mammography, a premier women's health company and the nation's largest independent provider of specialized breast health services, has been dedicated to elevating mammography services and maintaining breast health and peace of mind for almost 40 years. Headquartered in Addison, Texas, Solis Mammography operates more than 125 centers in 17 major markets, including Dallas-Fort Worth, Houston, Austin, South Texas, Utah, Denver, Phoenix, Tucson, Philadelphia, Columbus, Nashville, North Carolina, Miami, Ft. Lauderdale, and, through its affiliated brands Washington Radiology and Progressive Radiology, Washington D.C., Maryland, and Virginia. Solis Mammography is pioneering a boutique-style retail healthcare experience. The company operates both wholly owned centers and multiple successful joint venture partnerships with large hospital systems and prominent medical and academic institutions.
* * *
Original text here: https://www.mhs.net/news/2024/04/memorial-and-solis-mammography-open-breast-imaging-centers-in-weston-plantation-palm-springs-north
[Category: BizHealth Care]
MORGAN LEWIS ADDS GOVERNMENT CONTRACTS PARTNER ALEXANDER HASTINGS IN D.C.
WASHINGTON, April 19 -- Morgan Lewis, a law firm, issued the following news release on April 18, 2024:
Today, we welcome former Covington & Burling government contracts lawyer Alex Hastings as Morgan Lewis continues to expand its robust regulatory practice in Washington, DC. Joining as a partner, Alex will continue to advise companies that do business with government entities by counseling them through complex regulatory issues and M&A transactions.
"Many of our clients do business or collaborate with the US government, and they need sophisticated legal counsel," said Firm Chair Jami McKeon.
... Show Full Article
WASHINGTON, April 19 -- Morgan Lewis, a law firm, issued the following news release on April 18, 2024:
Today, we welcome former Covington & Burling government contracts lawyer Alex Hastings as Morgan Lewis continues to expand its robust regulatory practice in Washington, DC. Joining as a partner, Alex will continue to advise companies that do business with government entities by counseling them through complex regulatory issues and M&A transactions.
"Many of our clients do business or collaborate with the US government, and they need sophisticated legal counsel," said Firm Chair Jami McKeon."Alex brings added strength to our government contracts practice through a full suite of regulatory counseling that will benefit a broad spectrum of clients from pure-play defense contractors to commercial companies who are starting out in this area."
Alex helps aerospace and defense, life science, technology and commercial companies navigate legal and compliance matters that impact their business throughout the government contracting lifecycle, including issues related to intellectual property, supply chain challenges, cybersecurity, small business status, and conflicts of interests. Alex also advises transaction teams on the buy and sell sides involving government contractor due diligence reviews and transaction document negotiations.
"Alex joins forces with Barron Avery, who leads our government contracts practice and joined us in February 2022, and Justin Weitz, who spent nearly a decade in the DOJ's Criminal Division investigating and prosecuting government contracts and procurement fraud before his arrival in 2022," said J. Gordon Cooney Jr., leader of the firm's global litigation practice. "Adding the right skills to build strength on strength to support our clients is always our first priority."
Alex is the fifth partner with a deep regulatory background to join the firm in the last two weeks--four of which are based in the DC office--as we continue to strategically enrich our capabilities. Specifically, the firm recently welcomed April Nelson, Rachel Raphael, and Mohamed Awan--a consumer class action and product liability trio providing counsel in the highly regulated automotive industry, and transportation regulatory leader, R. Latane Montague.
* * *
Original text here: https://www.morganlewis.com/news/2024/04/morgan-lewis-adds-government-contracts-partner-alexander-hastings-in-dc
[Category: BizLaw/Legal]
Lauren Beames Co-Authors Article on Biodiversity Conventions for William & Mary Environmental Law and Policy Review
ORLANDO, Florida, April 19 -- Lowndes, a law firm, issued the following news release:
Lowndes attorney Lauren Beames co-authored an article in the William & Mary Environmental Law & Policy Review, exploring how four international biodiversity conventions emphasize biodiversity conservation's role in reducing zoonotic disease risks, particularly during the COVID-19 pandemic.
The article, titled "The Initial Response of Biodiversity Conventions to the COVID-19 Pandemic," is a collaboration between Beames, Professor Royal C. Gardner of Stetson University College of Law, and Katherine Pratt, also
... Show Full Article
ORLANDO, Florida, April 19 -- Lowndes, a law firm, issued the following news release:
Lowndes attorney Lauren Beames co-authored an article in the William & Mary Environmental Law & Policy Review, exploring how four international biodiversity conventions emphasize biodiversity conservation's role in reducing zoonotic disease risks, particularly during the COVID-19 pandemic.
The article, titled "The Initial Response of Biodiversity Conventions to the COVID-19 Pandemic," is a collaboration between Beames, Professor Royal C. Gardner of Stetson University College of Law, and Katherine Pratt, alsoof Stetson Law.
A graduate of Stetson Law, Beames is an associate in the firm's Litigation Department, where she focuses her practice in the areas of commercial, business, and real estate litigation.
* * *
Original text here: https://www.lowndes-law.com/newsroom/news/lauren-beames-co-authors-article-on-biodiversity-conventions-and-covid-19-for-william-mary-environmental-law-and-policy-review
[Category: BizLaw/Legal]
GSK: Eagle-1 Phase III Data Show Potential for Gepotidacin as a New Oral Treatment Option for Uncomplicated Urogenital Gonorrhoea Amid Growing Resistance to Existing Treatments
LONDON, England, April 19 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on April 17, 2024:
GSK plc (LSE/NYSE: GSK) today announced positive results from the pivotal EAGLE-1 phase III trial for gepotidacin, a potential first-in-class oral antibiotic with a novel mechanism of action for uncomplicated urogenital gonorrhoea (GC) in adolescents and adults. These results will be presented on 30 April 2024 at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global in Barcelona, Spain.
The results from EAGLE-1 are based
... Show Full Article
LONDON, England, April 19 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on April 17, 2024:
GSK plc (LSE/NYSE: GSK) today announced positive results from the pivotal EAGLE-1 phase III trial for gepotidacin, a potential first-in-class oral antibiotic with a novel mechanism of action for uncomplicated urogenital gonorrhoea (GC) in adolescents and adults. These results will be presented on 30 April 2024 at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global in Barcelona, Spain.
The results from EAGLE-1 are basedon a primary endpoint of microbiological response (success or failure of eliminating the bacterial cause of gonorrhoea) at the Test-of-Cure (ToC) visit 3-7 days after treatment. The trial showed that gepotidacin (oral, two doses of 3,000mg) was non-inferior with 92.6% success rates when compared to 91.2% success rates for intramuscular (IM) ceftriaxone (500mg) plus oral azithromycin (1,000mg) combined therapy, a leading combination treatment regimen for gonorrhoea.
The safety and tolerability profile of gepotidacin in the EAGLE-1 trial was consistent with results seen in phase I and II trials. The most commonly reported adverse events (AEs) in gepotidacin subjects were gastrointestinal (GI). All AEs were mild or moderate (Grade 1 or 2) except for one severe (Grade 3), unrelated event in each treatment arm and one unrelated serious event in the gepotidacin arm.
There are an estimated 82 million new cases of gonorrhoea globally each year.1 In the United States, rates of reported gonorrhoea have increased 118% from 2009 to 2021,2 with 648,056 cases being reported to the US Centers for Disease Control and Prevention (CDC) in 2022.3 The CDC also reported that approximately half of gonorrhoea cases each year in the US are resistant to one antibiotic.4
Chris Corsico, SVP Development, GSK, said: "These results highlight the potential of gepotidacin as a new oral treatment option given the rising incidence of gonorrhoea worldwide including drug resistant infections. The imperative for innovative treatments has never been clearer. We are committed to working with health regulators globally to introduce this potential new antibiotic, focusing on solutions that meet critical patient needs."
Gonorrhoea is a sexually transmitted infection caused by bacteria called Neisseria gonorrhoeae, which has been recognised by the World Health Organisation as a priority pathogen. It affects both men and women and if inadequately treated, it can lead to infertility and other sexual and reproductive health complications. It also increases the risk of HIV infection.
GSK is also developing gepotidacin for the potential treatment of uncomplicated urinary tract infections (uUTI). Positive phase III data from the EAGLE-2 and EAGLE-3 trials were presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in April 2023, and published in The Lancet.5 If approved, gepotidacin could be the first in a new class of oral antibiotics in uUTI in over 20 years. EAGLE-1 is the third positive pivotal trial for gepotidacin.
The development of gepotidacin has been funded in whole or in part with federal funds from the US Department of Health and Human Services, Administration for Strategic Preparedness and Response, Biomedical Advanced Research and Development Authority (BARDA), under Other Transaction Agreement number HHSO100201300011C and with federal funds awarded by the Defense Threat Reduction Agency under agreement number HDTRA1-07-9-0002.
About the EAGLE (Efficacy of Antibacterial Gepotidacin Evaluated) phase III programme
The global phase III clinical programme for gepotidacin in adults and adolescents has now been completed. The programme comprises of three trials:
EAGLE-1 (non-inferiority urogenital gonorrhoea trial) compared the efficacy and safety of gepotidacin to ceftriaxone plus azithromycin in approximately 600 patients with uncomplicated urogenital gonorrhoea.
EAGLE-2 and EAGLE-3 (non-inferiority uUTI trials) compared the efficacy and safety of gepotidacin (1,500mg administered orally twice daily for five days) to nitrofurantoin (100mg administered orally twice daily for five days). Across both trials, the duration for participants was approximately 28 days, and the primary endpoint was the combined clinical and microbiological response at the ToC visit (days 10-13) in patients with qualifying uropathogens susceptible to nitrofurantoin.
* * *
About Gepotidacin
Gepotidacin, discovered by GSK scientists, is an investigational bactericidal, first-in-class triazaacenaphthylene antibiotic that inhibits bacterial DNA replication by a novel mechanism of action and binding site and for most pathogens provides well-balanced inhibition of two different Type II topoisomerase enzymes. This provides activity against most strains of target uropathogens, (such as E. coli and S. saprophyticus), and N. gonorrhoeae, including isolates resistant to several antibiotics. Due to the well-balanced inhibition of two enzymes, gepotidacin target-specific mutations in both enzymes are needed to significantly affect gepotidacin susceptibility.
GSK in infectious diseases
GSK has pioneered innovation in infectious diseases for over 70 years, and the Company's pipeline of medicines and vaccines is one of the largest and most diverse in the industry. GSK's expertise and capabilities in innovation, access and stewardship position the Company uniquely to help prevent and mitigate the challenge of antimicrobial resistance. In antimicrobials, in addition to gepotidacin, GSK entered into an exclusive licence agreement with Spero Therapeutics, Inc. in September 2022 to add tebipenem HBr, a late-stage antibiotic and potential treatment for complicated urinary tract infections (cUTI), to the pipeline. In March 2023, GSK announced an exclusive licence agreement with Scynexis for Brexafemme (ibrexafungerp tablets), a first-in-class antifungal for the treatment of vulvovaginal candidiasis (VVC) and reduction in the incidence of recurrent VVC.
* * *
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.
* * *
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D "Risk factors" in the company's Annual Report on Form 20-F for 2023.
* * *
References
1. World Health Organisation, Multi-drug resistant gonorrhoea. Available at: https://www.who.int/news-room/fact-sheets/detail/multi-drug-resistant-gonorrhoea
2. CDC data on file
3. CDC, Sexually Transmitted Infections Surveillance. Available at: https://www.cdc.gov/std/statistics/2022/default.htm#:~:text=In%202022%2C%20more%20than%202.5,from%20all%20STI%20prevention%20partners
4. Centers for Disease Control and Prevention. Combating the Threat. Available at: https://www.cdc.gov/std/gonorrhea/drug-resistant/carb.htm#:~:text=There%20are%20more%20than%20500%2C000%20reported%20cases%20of,year%20are%20resistant%20to%20at%20least%20one%20antibiotic
5. The Lancet, Oral gepotidacin versus nitrofurantoin in patients with uncomplicated urinary tract infection (EAGLE-2 and EAGLE-3): two randomised, controlled, double-blind, double-dummy, phase 3, non-inferiority trials, available at: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)02196-7/abstract
* * *
Original text here: https://www.gsk.com/en-gb/media/press-releases/eagle-1-phase-iii-data-show-potential-for-gepotidacin-as-a-new-oral-treatment-option-for-uncomplicated-gc/
[Category: BizPharmaceuticals]
Applied Insight Wins Large, Multiyear Artificial Intelligence Development Contract From IC Customer
RESTON, Virginia, April 19 -- Applied Insight, a company that offers converged infrastructure, cyber operations, cloud computing and application development solutions, issued the following news release on April 18, 2024:
Applied Insight LLC, a cloud and technology services leader in the government market, announced today it has won a sizable and strategic five-year contract to provide artificial intelligence development to an existing U.S. Intelligence Community customer. Under the agreement, Applied Insight's work will primarily focus on various aspects of AI and machine learning.
"We are extremely
... Show Full Article
RESTON, Virginia, April 19 -- Applied Insight, a company that offers converged infrastructure, cyber operations, cloud computing and application development solutions, issued the following news release on April 18, 2024:
Applied Insight LLC, a cloud and technology services leader in the government market, announced today it has won a sizable and strategic five-year contract to provide artificial intelligence development to an existing U.S. Intelligence Community customer. Under the agreement, Applied Insight's work will primarily focus on various aspects of AI and machine learning.
"We are extremelygrateful to our customer for trusting our team to tackle this critical work in applying advanced AI technology to support our nation's national security mission," said Larry Denton, Chief Growth Officer at Applied Insight. "We are proud to expand our work with our customers to help maintain America's leadership in artificial intelligence. At the same time, we are thrilled about this huge team win. This is a major milestone for us that builds on the company's continuing cadence of new business. It's also proof of the quality work Applied Insight delivers and the deep knowledge and close collaborative relationships we have with our customers."
In the past 24 months, Applied Insight has won 12 contracts with national security customers, delivering services and products ranging from AI and cloud to cybersecurity and data analytics.
Earlier this year, Applied Insight acquired Zavda Technologies, further expanding its footprint in national security by strengthening its capabilities in network and systems engineering, data analysis, and software development to support the dynamic needs of defense and national security.
The Washington Business Journal has recognized Applied Insight as one of the Largest Government Technology Contractors and Largest Cybersecurity Companies in the Greater Washington area. Newsweek also recognized the company as one of America's Greatest Workplaces for Job Starters.
Applied Insight is actively recruiting to fill more than 100 job openings in Northern Virginia, Maryland, the District and other locations across the U.S. Job candidates may learn more about building a career at Applied Insight at http://www.applied-insight.com/careers/ and apply online at http://www.applied-insight.com/careers/open-positions/.
* * *
About Applied Insight
Applied Insight is a trusted go-to partner of government and industry for innovation in cloud, networking, data and cyber operations, renowned for its deep customer knowledge and rapid problem solving through a unique blend of human experience and technical expertise. Applied Insight's products and expertise have been honed and proven at the epicenter of the defense and intelligence mission. They apply that experience to design, deliver and manage highly secure cloud, networking, data, and cyber services and solutions across the public sector. Applied Insight has the scale to tackle the most complex challenges for our customers and the agility to solve them at the speed they demand. Learn more at applied-insight.com.
* * *
Original text here: https://www.applied-insight.com/applied-insight-wins-large-multiyear-artificial-intelligence-development-contract-from-ic-customer/
[Category: BizComputer Technology]
ABC's '9-1-1' 100th Episode Propels Series to No. 1 Drama in Primetime in Adults 18-49
BURBANK, California, April 19 -- ABC, a division of Walt Disney, issued the following news release:
* * *
Special Crossover Episode of '9-1-1' With 'The Bachelor' Is Top Program of the Night Among Adults 18-49, Reaching Season High With Linear Viewing
Series' Milestone 100th Featuring Joey Graziadei Scores Best L7 Rating Since May 2023
* * *
* Season to date and hot off its stellar season premiere and 8th season renewal, ABC's "9-1-1" ranks as the No. 1 drama in primetime in Adults 18-49 (tied), based on Most Current Data.
* The milestone 100th episode that featured a special crossover with
... Show Full Article
BURBANK, California, April 19 -- ABC, a division of Walt Disney, issued the following news release:
* * *
Special Crossover Episode of '9-1-1' With 'The Bachelor' Is Top Program of the Night Among Adults 18-49, Reaching Season High With Linear Viewing
Series' Milestone 100th Featuring Joey Graziadei Scores Best L7 Rating Since May 2023
* * *
* Season to date and hot off its stellar season premiere and 8th season renewal, ABC's "9-1-1" ranks as the No. 1 drama in primetime in Adults 18-49 (tied), based on Most Current Data.
* The milestone 100th episode that featured a special crossover with"The Bachelor"'s Joey Graziadei was the top program of the night, scoring a season-high on linear after 7 days of viewing in Adults 18-49 (0.91 rating), marking the show's best L7 rating since its season finale last year -- since 5/15/23.
* In addition, after 7 days of viewing across ABC, Hulu and digital platforms, the show's strong linear performance also lifted the show in the Adults 18-49 demo from the week prior (2.20 rating vs. 2.18 rating).
Source: The Nielsen Company, preliminary National Live + 7 Day Program Ratings and Multiplatform + 7 Day data for 4/4/24, or as dated. Most Current data, 2023-24 Season to date (9/25/23 - 4/7/24).
*COPYRIGHT Copyright (c) 2024 American Broadcasting Companies, Inc. All photography is copyrighted material and is for editorial use only. Images are not to be archived, altered, duplicated, resold, retransmitted or used for any other purposes without written permission of ABC. Images are distributed to the press in order to publicize current programming. Any other usage must be licensed.
* * *
Original text here: https://www.dgepress.com/abc/pressrelease/abcs-9-1-1-100th-episode-propels-series-to-no-1-drama-in-primetime-in-adults-18-49/
[Category: BizArts/Cultural]
